DOCSLIB.ORG

Amenorrhea—Etiologic Approach to Diagnosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Amenorrhea—Etiologic Approach to Diagnosis MODERN TRENDS'IltEl~DS Edward Wallach, M.D. Associate Editor FERTILITY AND STERILITY Vol. 30, No. I, July 1978 Copyright © 1978 The American Fertility Society Printed in U.S.A. AMENORRHEA-ETIOLOGIC APPROACH TO DIAGNOSIS PAUL G. McDONOUGH, M.D. Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Medical College of Georgia, Augusta, Georgia 30901 A delay in the initiation of menses at the time nated. All types of normally and ectopically lo­ of puberty or the interruption of an established cated trophoblastic proliferations should be menstrual pattern constitutes amenorrhea. Ces­ thought of collectively and suspected in every pa­ sation of menses normally occurs in the human tient who has a positive test for human chorionic female at the time of menopause. Failure to in­ gonadotropin. If suspicion of trophoblast persists itiate menses, interruption of a normal cyclic pat­ in spite of a negative routine pregnancy test, then tern of menses, or premature cessation of menses the more sensitive ,8-subunit human chorionic constitutes unphysiologic amenorrhea. Arbitrar­ gonadotropin determination should be performed. ily classifying menarchal failure and the inter­ Excluding the presence of active, viable, pro­ ruption of a normal cyclic menstrual pattern into liferating trophoblast in all patients with primary and secondary amenorrhea is largely amenorrhea should be the first consideration be­ semantic, since the same etiologic factors may be fore other etiologies are considered. operative in either instance. Over the past decade the evaluation of amen­ The average age for first menses is 13.5 years. orrhea has been assisted by advances and refine­ Menarche at chronologie ages 11 and 15 are 2 ments in diagnostic techniques. The diagnosis of standard deviations removed from the mean.1 The ovarian failure has been facilitated by the availa­ mean for the normal ovulatory menstrual inter­ bility of sensitive serum gonadotropin measure­ val is 28 days, and ranges around that interval ments. Improved techniques of chromosomal extend from 21 to 44 days.2 The average age for banding ensure a confident diagnosis of the sex cessation of menses is 49, with ranges from 35 to chromosome abnormalities associated with 55 years. Departure from these norms constitutes amenorrhea. Laparoscopic techniques have pro­ at least temporary failure of the cycling mecha­ vided an easy means of visualizing the gonads, nism with clinical amenorrhea. An arbitrary rule and polytomography of the sella turcica assisted of thumb as to what constitutes significant by computerized axial tomography (the CAT pathologic amenorrhea is difficult to define and scan) has improved the early diagnosis of pitui­ has very little use clinically. It is the concern or tary tumors. A specific radioimmunoassay for anxiety of the patient, regardless of the duration serum prolactin has provided a sensitive indicator of amenorrhea, that prompts her visit to the of hypothalamic-pituitary dysfunction and physician. For example, interruption of the cy­ prolactin-secreting pituitary microadenomas. cling mechanism due to pr.egnancy should be Plasma levels of testosterone, growth hormone, diagnosed as soon as possible. A delay of 3 to 6 and cortisol are readily available through com­ months in the diagnosis of other causes of mercial laboratories. The general trend is toward amenorrhea does not create any harm or undue the direct measurement of pituitary polypeptides anxiety for the patient if the presence of preg­ and steroids in blood rather than their counter­ nancy or trophoblastic disease has been elimi- parts or metabolites in urine. This general switchover from urine to blood and from milli­ Received January 3, 1978. *Reprint requests: Paul G. McDonough, M.D., Department of grams to nanograms and picograms has created a Obstetrics and Gynecology, Medical College of Georgia, 1120 new dimension that the physician must master. 15th Street, Augusta, Ga. 30901. Lastly, the isolation of gonadotropin-releasing I 1 I I -v I 2 MCDONOUGH July 1978 hormone (GnRH) and other potent analogs pro­ TABLE 1. Etiology of Amenorrhea vides for a dynamic test of hypothalamic­ Eugonadotropic amenorrhea pituitary function. Nonfunctional uterus In spite of these improvements in diagnostic Congenital (Rokitansky syndrome) Acquired (Asherman's syndrome) techniques, a careful history and physical exami­ Functional uterus with obstruction nation with appropriately selected laboratory Hypergonadotropic amenorrhea studies remain paramount in the evaluation of Chromosomally incompetent ovarian failure (CIOF) Chromosomally competent ovarian failure (CCOF) amenorrhea. The clinician's acumen should in­ 46,XY forms clude a perspective of the different etiologies of Swyer's syndrome (XY gonadal dysgenesis) amenorrhea, their relative frequency, and an Congenital androgen insensitivity syndrome 46,XX forms acute awareness of any particular causes which Autosomal recessive gene may compromise the life-span or fertility of the Environmental factors patient. Autosomal abnormalities Infectious infiltrative disease Autoimmune disease Gonadotropin-resistant ovary (Savage syndrome) ETIOLOGY 17 -Hydroxylase deficiency Hypogonadotropic amenorrhea The etiologies of amenorrhea which preclude Congenital (Kallmann's syndrome) menarche tend to be represented by genetic Acquired causes or anatomical maldevelopments of the Pituitary tumors and necrosis Drug-induced amenorrhea genital tract. In contrast, the interruption of an Psychogenic amenorrhea established cyclic pattern of menses is usually Stress-induced tonic LH (short-term) psychogenic in origin. One should appreciate the Stress-induced tonic LH (long-term) Hypogonadotropism (stress, nutrition) high frequency of genetic causes in the patient Hypogonadotropic hyperprolactinemia with primary amenorrhea and the relatively high Systemic illness-endocrine frequency of psychogenic factors in patients with Thyroid (hyper, hypo) Adrenal (hyper, hypo) secondary amenorrhea. The approach to an Systemic illness-non-endocrine evaluation of these high-frequency groups will be Amenorrhea and galactorrhea stressed. Androgen excess Adrenal tumor The spectrum of pathology seen in association Congenital adrenal hyperplasia with amenorrhea is varied, but certain well­ Virilizing ovarian tumors defined categories are recognizable. These Androgenic ovary syndrome categories can be broadly grouped into eugonad­ otropic amenorrhea, hypergonadotropic amen­ orrhea, hypogonadotropic amenorrhea, and rian anlagen. The bilateral hypoplastic discrete amenorrhea occurring in association with andro­ uteri seen in these individuals are associated with gen excess (Table 1). The separation of the total vaginal agenesis. Ovarian endocrine func­ amenorrheas into these four large groups facili­ tion and exocrine function are normal. The failure tates the diagnosis. The first two groups are more of the two Mullerian anlagen to fuse completely often associated with menarchal delay, whereas eliminates the natural stimulus for normal the hypogonadotropic group usually presents canalization of the vagina by upgrowth of urogen­ with secondary amenorrhea. Disorders of andro­ ital sinus epithelium. Developmental abnor­ gen excess may produce primary or secondary malities of the kidneys occur frequently in these amenorrhea, but are more frequently associated individuals. The most frequent renal malforma­ with the latter. tion is a solitary ectopic kidney located in the pel­ vis. Skeletal abnormalities such as mild to severe Eugonadotropic Amenorrhea scoliosis and Klippel-Feil deformity occasionally occur in association with the Rokitansky­ Nonfunctional Uterus Kuster-Hauser syndrome. The etiology of this syndrome remains obscure. The high frequency of Congenital. sporadic cases tends to incriminate an autosomal recessive gene or an environmental factor affect­ The most frequent anatomical cause of primary ing early development of the mesonephric and amenorrhea is the Rokitansky-Kuster-Hauser paramesonephric system. Identical twins discor­ syndrome. 3 • 4 This syndrome is characterized by dant for Rokitansky-Kuster-Hauser syndrome hypoplasia and failure of fusion of the two Mulle- have been reviewed by Lischke et al. 5 Discordance Vol. 30, No.1 AMENORRHEA-ETIOLOGIC APPROACH TO DIAGNOSIS 3 in monozygotic twins suggests that differential diagnosis. On a few occasions after a missed abor­ environmental factors are operative in utero. tion, nonviable hyalinized or calcific villi may Individuals with the Rokitansky-Kuster­ remain in the uterus and produce anatomical Hauser syndrome are usually asymptomatic ex­ amenorrhea. Pregnancy testing is negative in cept for menarchal delay, and present with nor­ these patients, and endometrial biopsy or curet­ mal somatic and sexual development. Total ab­ tage is necessary to establish the diagnosis. sence of the vagina or the presence of a small A form of endometrial refractoriness due to vaginal pouch is usually the only physical temporary involution of the endometrial glands finding. Cytogenetic studies confirm a normal may occur following discontinuation of oral contra­ 46,XX karyotype, and the basal body temperature ceptives or after the use of injectable synthetic graph is biphasic. The occurrence of normal ad­ steroids such as Depo-Provera. This form of renarche and normal female levels of serum tes­ amenorrhea, due to target-organ unresponsive­ tosterone exclude the diagnosis of congenital an­ ness, needs to be distinguished from the hypo­ drogen insensitivity
Load more

Recommended publications
  • Androgen Excess in Breast Cancer Development: Implications for Prevention and Treatment
    26 2 Endocrine-Related G Secreto et al. Androgen excess in breast 26:2 R81–R94 Cancer cancer development REVIEW Androgen excess in breast cancer development: implications for prevention and treatment Giorgio Secreto1, Alessandro Girombelli2 and Vittorio Krogh1 1Epidemiology and Prevention Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milano, Italy 2Anesthesia and Critical Care Medicine, ASST – Grande Ospedale Metropolitano Niguarda, Milano, Italy Correspondence should be addressed to G Secreto: [email protected] Abstract The aim of this review is to highlight the pivotal role of androgen excess in the Key Words development of breast cancer. Available evidence suggests that testosterone f breast cancer controls breast epithelial growth through a balanced interaction between its two f ER-positive active metabolites: cell proliferation is promoted by estradiol while it is inhibited by f ER-negative dihydrotestosterone. A chronic overproduction of testosterone (e.g. ovarian stromal f androgen/estrogen balance hyperplasia) results in an increased estrogen production and cell proliferation that f androgen excess are no longer counterbalanced by dihydrotestosterone. This shift in the androgen/ f testosterone estrogen balance partakes in the genesis of ER-positive tumors. The mammary gland f estradiol is a modified apocrine gland, a fact rarely considered in breast carcinogenesis. When f dihydrotestosterone stimulated by androgens, apocrine cells synthesize epidermal growth factor (EGF) that triggers the ErbB family receptors. These include the EGF receptor and the human epithelial growth factor 2, both well known for stimulating cellular proliferation. As a result, an excessive production of androgens is capable of directly stimulating growth in apocrine and apocrine-like tumors, a subset of ER-negative/AR-positive tumors.
    [Show full text]
  • Endometriosis and PCOS: Two Major Pathologies Linked to Oxidative Stress in Women Sajal Gupta1, Avi Harlev1 and Ashok Agarwal1
    Chapter 5 Chapter 5 Endometriosis and PCOS: Two major pathologies… Endometriosis and PCOS: Two major pathologies linked to oxidative stress in women Sajal Gupta1, Avi Harlev1 and Ashok Agarwal1 Introduction Oxidative stress (OS) ensues when the detrimental activity of reactive oxygen species (ROS) prevails over that of anti-oxidants causing lipid peroxidation, protein carbonylation, and DNA damage and/or cell apoptosis. Moreover, reactive nitrogen species (RNS), such as nitrogen oxide (NO) with an unpaired electron, is also highly reactive and toxic (Agarwal et al. 2012, Doshi et al. 2012). OS has been known to participate in the pathogenesis of PCOS and endometriosis. Several OS biomarkers have been scrutinized by investigators, in the past, including MDA (malondialdehyde), protein carbonyl, TAC (total antioxidant capacity), SOD (superoxide dismutase), GPx (glutathione peroxidase), and GSH (reduced glutathione) to determine the role of OS in PCOS (Azziz et al.) and endometriosis (Jackson et al. 2005, Murri et al. 2013). Free radicals are known to impact several microenvironments in different biological windows, such as in the follicular microenvironment (Gonzalez et al. 2006, Murri et al. 2013). Both PCOS and endometriosis are associated with poor oocyte quality and infertility (Gupta et al. 2008, Goud et al. 2014, Huang et al. 2015). Our current review addresses the role of OS in both these disease conditions and the role of antioxidants and lifestyle modifications in preempting the impact of free radicals in PCOS and endometriosis. Polycystic ovary syndrome (PCOS) is a multicomponent disorder affecting many adolescent girls as well as women of reproductive age, characteristically 1 Affiliation: 1 Center for Reproductive Medicine, 10681 Carnegie Avenue, Glickman Urology & Kidney Institute, Cleveland Clinic, Cleveland, Ohio-44195.
    [Show full text]
  • Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
    Published OnlineFirst November 15, 2017; DOI: 10.1158/1055-9965.EPI-17-0655 Research Article Cancer Epidemiology, Biomarkers Polycystic Ovary Syndrome, Oligomenorrhea, and & Prevention Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium Holly R. Harris1, Ana Babic2, Penelope M. Webb3,4, Christina M. Nagle3, Susan J. Jordan3,5, on behalf of the Australian Ovarian Cancer Study Group4; Harvey A. Risch6, Mary Anne Rossing1,7, Jennifer A. Doherty8, Marc T.Goodman9,10, Francesmary Modugno11, Roberta B. Ness12, Kirsten B. Moysich13, Susanne K. Kjær14,15, Estrid Høgdall14,16, Allan Jensen14, Joellen M. Schildkraut17, Andrew Berchuck18, Daniel W. Cramer19,20, Elisa V. Bandera21, Nicolas Wentzensen22, Joanne Kotsopoulos23, Steven A. Narod23, † Catherine M. Phelan24, , John R. McLaughlin25, Hoda Anton-Culver26, Argyrios Ziogas26, Celeste L. Pearce27,28, Anna H. Wu28, and Kathryn L. Terry19,20, on behalf of the Ovarian Cancer Association Consortium Abstract Background: Polycystic ovary syndrome (PCOS), and one of its cancer was also observed among women who reported irregular distinguishing characteristics, oligomenorrhea, have both been menstrual cycles compared with women with regular cycles (OR ¼ associated with ovarian cancer risk in some but not all studies. 0.83; 95% CI ¼ 0.76–0.89). No significant association was However, these associations have been rarely examined by observed between self-reported PCOS and invasive ovarian cancer ovarian cancer histotypes, which may explain the lack of clear risk (OR ¼ 0.87; 95% CI ¼ 0.65–1.15). There was a decreased risk associations reported in previous studies. of all individual invasive histotypes for women with menstrual Methods: We analyzed data from 14 case–control studies cycle length >35 days, but no association with serous borderline including 16,594 women with invasive ovarian cancer (n ¼ tumors (Pheterogeneity ¼ 0.006).
    [Show full text]
  • Ultrasonographic Prevalence of Polycystic Ovarian Disease – a Cross-Sectional Study in a Rural Medical College of West Bengal
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 15, Issue 1 Ver. X (Jan. 2016), PP 115-120 www.iosrjournals.org Ultrasonographic Prevalence of Polycystic Ovarian Disease – A Cross-Sectional Study in a Rural Medical College of West Bengal Monojit Chakrabarti1, Md Abdur Rahaman2, Swadha Priyo Basu3 1(Assistant Professor, Dept. of Radiology, Malda Medical College & Hospital, West Bengal, India) 2(R.M.O. cum Clinical Tutor, Dept. of Radiology, Malda Medical College & Hospital, West Bengal, India ) 3(Professor & HOD, Dept. of Radiology, Malda Medical College & Hospital, West Bengal, India ) Abstract : Introduction: Polycystic ovary disease (PCOD) is the most common and complex endocrinal disorder of females in their early child bearing age group. It may complicated to Infertility. Methodology: Trans Abdominal Ultrasonography was carried out over 157 women in a rural medical college of West Bengal and 51 females were diagnosed of PCOD using Rotterdam’s criteria. Results: Maximum prevalence of PCOD was seen between 15 to 24 years age group. Dominantly oligomenorrhea was seen among PCOD (75%) patients. 33.4% obese patients were diagnosed PCOD. Conclusion: It is commonly observed in early child bearing age group, especially those females having oligomenorrhea. Lifestyle management is now considered one of the principal way to deal with PCOS. Keywords: Anovulation, B.M.I. (Body Mass Index), Oligomenorrhea, Polycystic Ovarian Disease (PCOD), Trans Abdominal Ultrasound (TAS). I. Introduction Polycystic ovarian disease (PCOD) is the most common and complex endocrinal disorder affecting females of child bearing age1. It is also known as Hyperandrogenic Anovulation and Stein-Leventhal Syndrome2,3.
    [Show full text]
  • Estrogen Deficiency During Menopause and Its Management: a Current Update V
    Review Article Estrogen deficiency during menopause and its management: A current update V. T. Hemalatha1, A. Julius2, S. P. Kishore Kumar3, L. Vijayalakshmi4, Shankar Narayanan1 ABSTRACT Different phases of a woman’s life: Puberty, menses, pregnancy, and menopause have varied influence on her oral health. During the menopause, women go through biological and endocrine changes, particularly in their sex steroid hormone production, affecting their health. Sex hormones strongly influence body fat distribution and adipocyte differentiation. Estrogens and testosterone differentially affect adipocyte physiology, but the importance of estrogens in the development of metabolic diseases during menopause is disputed. Estrogens and estrogens receptor regulate various aspects of glucose and lipid metabolism. Disturbances of this metabolic signal lead to the development of metabolic syndrome and a higher cardiovascular risk in woman. The absence of estrogens is a clue factor in the onset of cardiovascular disease during the menopausal period, which is characterized by lipid profile variations and predominant abdominal fat accumulation. However, influence of the absence of these hormones and its relationship to higher obesity in women during menopause is not clear. This systematic review discusses of the role of estrogens and estrogen receptors in adipocyte differentiation and its various effects and brief discussion on its management. KEY WORDS: Estrogen hormone (estrogens/progestogens) replacement therapy, Menopause, Weight gain INTRODUCTION BODY CHANGES AT MENOPAUSE Menopause occurs when a woman stops ovulating and As we age, our muscles decrease in bulk and our her monthly period (menstruation) stops. metabolism slows down. These changes cancontribute to weight gain around the time of menopause. Other As women age, into their 40s and 50s, there is a tendency physical changes associated with menopause may to gain weight.
    [Show full text]
  • 1.Management of Abnormal Uterine Bleeding
    SLCOG National Guidelines Management of Abnormal Uterine Bleeding Contents Page 1.Management of Abnormal 1.1 Scope of the guideline 3 1.1.1 Definition 3 Uterine Bleeding 1.2 Differential diagnosis 5 1.3 Assessment 1.3.1 Abnormal Uterine Bleeding in Teenage Girls 1.3.2 Abnormal Uterine Bleeding in Women 8 of Childbearing Age 1.3.3 Abnormal Uterine Bleeding in 11 Peri-Menopausal Women 1.3.4 Abnormal Uterine Bleeding in 14 Post-Menopausal Women 1.4 Treatment of Abnormal Uterine Bleeding 19 1.4.1 Medical Management 19 1.4.2 Surgical Management 22 1.5 References 25 Contributed by Prof C. Randeniya Prof H.R. Senevirathne Dr. H.S. Dodampahala Dr. N. Senevirathne Dr. R Sriskanthan Printing and manuscript reading Dr. S. Senanayake Dr C.S. Warusawitharana 2 Management of Abnormal Uterine Bleeding SLCOG National Guidelines before menarche can be abnormal. In women of Introduction childbearing age, abnormal uterine bleeding includes any The aim of this Guideline is to provide recommendations change in menstrual-period frequency or duration, or to aid General Practitioners and Gynaecologists in the amount of flow, as well as bleeding between cycles. In management of Abnormal Uterine Bleeding (AUB). This postmenopausal women, abnormal uterine bleeding includes vaginal bleeding six months or more after the treatment could be initiated in a primary care setting or in centres with advanced facilities. The objective of treatment cessation of menses, or unpredictable bleeding in in AUB is to alleviate heavy menstrual flow to make a postmenopausal women who have been receiving hormone therapy for 12 months or more.
    [Show full text]
  • How to Evaluate Vaginal Bleeding and Discharge
    How to Evaluate Vaginal Bleeding and Discharge Is the bleeding normal or abnormal? When does vaginal discharge reflect something as innocuous as irritation caused by a new soap? And when does it signal something more serious? The authors’ discussion of eight actual patient presentations will help you through the next differential diagnosis for a woman with vulvovaginal complaints. By Vincent Ball, MD, MAJ, USA, Diane Devita, MD, FACEP, LTC, USA, and Warren Johnson, MD, CPT, USA bnormal vaginal bleeding or discharge is typically due to either inadequate levels of estrogen one of the most common reasons women or a persistent corpus luteum. Structural causes of come to the emergency department.1,2 bleeding include leiomyomas, endometrial polyps, or Because the possible underlying causes malignancy. Infectious etiologies include pelvic in- Aare diverse, the patient’s age, key historical factors, flammatory disease (PID). Additionally, a variety of and a directed physical examination are instrumental bleeding dyscrasias involving platelet or clotting fac- in deciding on diagnosis and treatment. This article tors can complicate the normal menstrual period. Iat- will review some common case presentations of rogenic causes of vaginal bleeding include hormone nonpregnant female patients with abnormal vaginal replacement therapy, steroid hormone contraception, bleeding, inflammation, or discharge. and contraceptive intrauterine devices.3-5 Anovulatory bleeding is common in perimenar- ABNORMAL VAGINAL BLEEDING chal girls as a result of an immature hypothalamic- To ensure appropriate patient management, “Is she pituitary axis and in perimenopausal women due to pregnant?” should be the first question addressed, declining levels of estrogen. During reproductive since some vulvovaginal signs and symptoms will years, dysfunctional uterine differ in significance and urgency depending on the bleeding (DUB) is the most >>FAST TRACK<< answer.
    [Show full text]
  • Changes Before the Change1.06 MB
    Changes before the Change Perimenopausal bleeding Although some women may abruptly stop having periods leading up to the menopause, many will notice changes in patterns and irregular bleeding. Whilst this can be a natural phase in your life, it may be important to see your healthcare professional to rule out other health conditions if other worrying symptoms occur. For further information visit www.imsociety.org International Menopause Society, PO Box 751, Cornwall TR2 4WD Tel: +44 01726 884 221 Email: [email protected] Changes before the Change Perimenopausal bleeding What is menopause? Strictly defined, menopause is the last menstrual period. It defines the end of a woman’s reproductive years as her ovaries run out of eggs. Now the cells in the ovary are producing less and less hormones and menstruation eventually stops. What is perimenopause? On average, the perimenopause can last one to four years. It is the period of time preceding and just after the menopause itself. In industrialized countries, the median age of onset of the perimenopause is 47.5 years. However, this is highly variable. It is important to note that menopause itself occurs on average at age 51 and can occur between ages 45 to 55. Actually the time to one’s last menstrual period is defined as the perimenopausal transition. Often the transition can even last longer, five to seven years. What hormonal changes occur during the perimenopause? When a woman cycles, she produces two major hormones, Estrogen and Progesterone. Both of these hormones come from the cells surrounding the eggs. Estrogen is needed for the uterine lining to grow and Progesterone is produced when the egg is released at ovulation.
    [Show full text]
  • Management of Women with Premature Ovarian Insufficiency
    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
    [Show full text]
  • A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
    Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies.
    [Show full text]
  • Selected Topics in WOMEN’S HEALTH
    www.bpac.org.nz keyword: womenshealth Selected topics in WOMEN’S HEALTH Laboratory investigation of amenorrhoea Polycystic ovary syndrome An overview of dysfunctional uterine bleeding Perimenopause and menopause Sexual dysfunction - loss of libido 8 | September 2010 | best tests Amenorrhoea Amenorrhoea is the absence of menstruation flow. It can Causes of primary amenorrhoea2 be classified as either primary or secondary,1 relative to menarche: ■ Hypergonadotropic hypogonadism/primary hypogonadism/gonadal failure: ■ Primary amenorrhoea: absence of menses by age 16 years in a female with appropriate development – Abnormal sex chromosomes e.g. Turner of secondary sexual characteristics; or absence syndrome of menses by age 13 years and no other pubertal – Normal sex chromosomes e.g. premature maturation2 ovarian failure ■ Secondary amenorrhoea: lack of menses in a ■ Hypogonadotropic hypogonadism/secondary previously menstruating, non-pregnant female, for hypogonadism: 2 greater than six months – In many cases this may be due to a familial delay in puberty and growth. Other causes include congenital abnormalities Primary amenorrhoea e.g. isolated GnRH deficiency, acquired Key messages: lesions, endocrine disturbance, tumour, systemic illness or eating disorder. ■ The most common cause of primary amenorrhoea in a female with no secondary sexual characteristics ■ Eugonadism: is a constitutional delay in growth and puberty. – Anatomic e.g. congenital absence of the In the first instance, watchful waiting is the most uterus and vagina, intersex
    [Show full text]
  • A Novel Null Mutation in P450 Aromatase Gene (CYP19A1
    J Clin Res Pediatr Endocrinol 2016;8(2):205-210 DO I: 10.4274/jcrpe.2761 Ori gi nal Ar tic le A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans Sema Akçurin1, Doğa Türkkahraman2, Woo-Young Kim3, Erdem Durmaz4, Jae-Gook Shin3, Su-Jun Lee3 1Akdeniz University Faculty of Medicine Hospital, Department of Pediatric Endocrinology, Antalya, Turkey 2Antalya Training and Research Hospital, Clinic of Pediatric Endocrinology, Antalya, Turkey 3 Inje University College of Medicine, Department of Pharmacology, Inje University, Busan, Korea 4İzmir University Faculty of Medicine, Medical Park Hospital, Clinic of Pediatric Endocrinology, İzmir, Turkey ABS TRACT Objective: The CYP19A1 gene product aromatase is responsible for estrogen synthesis and androgen/estrogen equilibrium in many tissues, particularly in the placenta and gonads. Aromatase deficiency can cause various clinical phenotypes resulting from excessive androgen accumulation and insufficient estrogen synthesis during the pre- and postnatal periods. In this study, our aim was to determine the clinical characteristics and CYP19A1 mutations in three patients from a large Turkish pedigree. Methods: The cases were the newborns referred to our clinic for clitoromegaly and labial fusion. Virilizing signs such as severe acne formation, voice deepening, and clitoromegaly were noted in the mothers during pregnancy. Preliminary diagnosis was aromatase deficiency. Therefore, direct DNA sequencing of CYP19A1 was performed in samples from parents (n=5) and patients (n=3). WHAT IS ALREADY KNOWN ON THIS TOPIC? Results: In all patients, a novel homozygous insertion mutation in the fifth exon (568insC) was found to cause a frameshift in the open reading frame and to truncate Aromatase deficiency can cause various clinical phenotypes the protein prior to the heme-binding region which is crucial for enzymatic activity.
    [Show full text]